J Oncol Pharm Pract:在口服化疗中医生-药剂师合作相得益彰

2015-04-24 范伟译 MedSci原创

背景: 口服化疗经常用于转移性阉割-抵抗的前列腺癌和肾细胞癌。虽然方便,但这些药物需要监测其依从性、毒性、药物间相互作用的最大化结果。肿瘤学药剂师具备的训练和专业知识,而使他们把提供药物治疗管理的合作摆在最优位置。方法: 从业肿瘤学药剂师,与医学肿瘤学家合作,发起的口服化疗的监测项目。药剂师提供教育、完成药物治疗管理;监测依从性和毒性,推荐治疗的毒性和支持性护理问题。拜访的病人包括下列之一:医学肿

背景: 口服化疗经常用于转移性阉割-抵抗的前列腺癌和肾细胞癌。虽然方便,但这些药物需要监测其依从性、毒性、药物间相互作用的最大化结果。肿瘤学药剂师具备的训练和专业知识,而使他们把提供药物治疗管理的合作摆在最优位置。

方法: 从业肿瘤学药剂师,与医学肿瘤学家合作,发起的口服化疗的监测项目。药剂师提供教育、完成药物治疗管理;监测依从性和毒性,推荐治疗的毒性和支持性护理问题。拜访的病人包括下列之一:医学肿瘤学家,药剂师合作寻访的,或访问期间电话或电子邮件跟进的。

结果: 从2012年12月到2014年5月,药剂师的123名拜访的人中20名有转移性前列腺癌患者(n = 17)或肾细胞癌(n = 3)。所有患者为男性(平均年龄80岁)。大多数拜访的患者都在诊所,与医师合作寻访的或独自一人的(52%);36%的为电话拜访的,11.3%的为电子邮件跟进。在315个评估意见中25%的为药物相关的问题。问题包括:药品不良反应,40%;不适当的治疗,20%;不符合,18%。建议包括:实验室监测的更改,25%;癌症或非癌症治疗的修改,12%;停药,6.9%。非癌症治疗-相关的药物信息和协调护理占到建议的30%。

结论: 我们的项目推动了患者口服化疗的许多潜在的重大临床问题的确定,并表明了药剂师在多学科团队协助解决问题中的作用。

原始出处:

Holle LM1, Puri S2, Clement JM3. Physician-pharmacist collaboration for oral chemotherapy monitoring: Insights from an academic genitourinary oncology practice. J Oncol Pharm Pract. 2015 Apr 21
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1864645, encodeId=711118646452a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Dec 11 18:50:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787171, encodeId=6e281e8717109, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Mar 14 09:50:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22067, encodeId=97532206ed9, content=是好事, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sun Apr 26 19:32:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604649, encodeId=f358160464908, content=<a href='/topic/show?id=decf8e3276c' target=_blank style='color:#2F92EE;'>#药剂师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87327, encryptionId=decf8e3276c, topicName=药剂师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8719252633, createdName=贵阳, createdTime=Sun Apr 26 02:50:00 CST 2015, time=2015-04-26, status=1, ipAttribution=)]
    2015-12-11 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1864645, encodeId=711118646452a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Dec 11 18:50:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787171, encodeId=6e281e8717109, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Mar 14 09:50:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22067, encodeId=97532206ed9, content=是好事, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sun Apr 26 19:32:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604649, encodeId=f358160464908, content=<a href='/topic/show?id=decf8e3276c' target=_blank style='color:#2F92EE;'>#药剂师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87327, encryptionId=decf8e3276c, topicName=药剂师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8719252633, createdName=贵阳, createdTime=Sun Apr 26 02:50:00 CST 2015, time=2015-04-26, status=1, ipAttribution=)]
    2016-03-14 jj000001
  3. [GetPortalCommentsPageByObjectIdResponse(id=1864645, encodeId=711118646452a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Dec 11 18:50:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787171, encodeId=6e281e8717109, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Mar 14 09:50:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22067, encodeId=97532206ed9, content=是好事, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sun Apr 26 19:32:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604649, encodeId=f358160464908, content=<a href='/topic/show?id=decf8e3276c' target=_blank style='color:#2F92EE;'>#药剂师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87327, encryptionId=decf8e3276c, topicName=药剂师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8719252633, createdName=贵阳, createdTime=Sun Apr 26 02:50:00 CST 2015, time=2015-04-26, status=1, ipAttribution=)]
    2015-04-26 zhouanxiu

    是好事

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1864645, encodeId=711118646452a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Dec 11 18:50:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787171, encodeId=6e281e8717109, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Mar 14 09:50:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22067, encodeId=97532206ed9, content=是好事, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sun Apr 26 19:32:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604649, encodeId=f358160464908, content=<a href='/topic/show?id=decf8e3276c' target=_blank style='color:#2F92EE;'>#药剂师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87327, encryptionId=decf8e3276c, topicName=药剂师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8719252633, createdName=贵阳, createdTime=Sun Apr 26 02:50:00 CST 2015, time=2015-04-26, status=1, ipAttribution=)]
    2015-04-26 贵阳